Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors

Song, Jeong Yeop; Lee, Yun Nah; Kim, Young Seok; Kim, Sang Gyune; Jin, Soo Ji; Park, Sungha; Choi, Gyu Seong; Chung, Jun Chul; Lee, Min Hee; Cho, Youn Hee; Choi, Moon Han; Kim, Dong Choon; Choi, Hyun Jong; Moon, Jong Ho; Lee, Se Hwan; Jeong, Sang Won; Jang, Jae Young; Kim, Hong Soo; Kim, Boo Sung

doi:10.1097/mnm.0000000000000254

Cited by 21 publications

(9 citation statements)

References 45 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In BTCs, studies about the issues are limited. Preoperative metabolic activity in BTCs was associated with recurrence risk and survival outcome (12,13). In the metastatic setting, Kitamura et al showed that SUV max was associated with OS; however, this study included only patients with EHCC and evaluated only the metabolism at the primary tumor site (14).…”

Section: Discussionmentioning

confidence: 99%

“…Studies focusing on the tumor metabolism of BTCs are limited, and a small number of the studies are mostly retrospective data and have some barriers to the clinical application (12)(13)(14)(15)(16). We previously reported that the tumor metabolism of BTC assessed by 18 F-FDG PET before chemotherapy had a prognostic value identified by retrospective analysis (17).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Kwon

Park

et al. 2017

J Nucl Med

View full text Add to dashboard Cite

Tumor metabolism measured by F-FDG PET has a diagnostic and prognostic role in several cancers. The clinical implication of tumor metabolism in biliary tract cancer (BTC) has not been studied well. Therefore, we evaluated the prognostic value of tumor metabolism and chemotherapy-related changes in advanced BTC patients. We prospectively enrolled advanced BTC patients before the initiation of palliative chemotherapy. Using F-FDG PET, we assessed the baseline SUV and monitored the changes in SUV during chemotherapy. We analyzed the associations between SUV, and clinicopathologic factors and clinical outcomes. Seventy-five patients were enrolled. All patients received gemcitabine/cisplatin as first-line chemotherapy. Primary tumor site, histologic differentiation, molecular characteristics, laboratory findings, and disease extent were associated with the metabolic characteristics. The high-metabolism group showed worse survival outcome (hazard ratio [HR] = 4.09, = 0.001 for progression-free survival; HR = 2.61, = 0.019 for overall survival [OS]) than the low-metabolism group. The lesser reduction of SUV was also associated with worse outcome (HR = 3.35, = 0.002 for progression-free survival; HR = 1.96, = 0.082 for OS). When both baseline tumor metabolism and its chemotherapy-related changes were considered, patients with a low metabolism and more reduction in metabolism obtained the best OS (20.7 vs. 6.2 mo, = 0.013). Tumor metabolic activity and the chemotherapy-related changes in the metabolism are associated with prognosis in advanced BTC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Kwon

Park

et al. 2017

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…In multimodality treatment, chemotherapy can control micrometastasis as well as play the role of a radiosensitizer (30). Because HCCs with aggressive features and rapid tumor growth show high 18 F-FDG uptake (15,31), the efficacy of multimodality treatment might be more prominent in patients with a high 18 F-FDG uptake than that of monotherapy. This hypothesis may explain why patients treated with CCRT, a multimodality treatment, had better PFS and OS than those with TACE as a monotherapy, particularly among patients with a high 18 F-FDG uptake.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study

Lee

Chung

et al. 2016

J Nucl Med

View full text Add to dashboard Cite

This study aimed to assess the prognostic value of 18 F-FDG uptake in hepatocellular carcinoma (HCC) patients who had transarterial chemoembolization (TACE) or concurrent intraarterial chemotherapy with external-beam radiotherapy (CCRT) and to compare the prognosis between patients treated with TACE and those with CCRT according to 18 F-FDG uptake. Methods: Two hundred fourteen intermediateto-advanced-stage HCC patients without extrahepatic metastasis who underwent staging 18 F-FDG PET/CT before TACE (153 patients) or CCRT (61 patients) were recruited from 7 hospitals. Progressionfree survival (PFS) and overall survival (OS) were compared using an optimal cutoff value for tumor-to-normal liver uptake ratio (TLR). Further, PFS and OS were compared according to treatment modalities (TACE vs. CCRT) using the same TLR cutoff value. Results: On multivariate analysis, age and TLR were independent prognostic factors for PFS (P , 0.050). For OS, Child-Pugh classification and TLR were independent prognostic factors (P , 0.050). When the TLR was greater than 2.0, patients treated with CCRT showed significantly better PFS and OS than those treated with TACE after adjusting for tumor size and number (P 5 0.014, for all). In contrast, there was no significant difference in PFS and OS between patients treated with TACE or CCRT when the TLR was 2.0 or less. Conclusion: 18 F-FDG uptake was an independent prognostic factor for PFS and OS in HCC patients treated with TACE or CCRT. Especially, in HCCs with high 18 F-FDG uptake, patients treated with CCRT showed better survival than those treated with TACE.

show abstract

“…Positron-emission tomography (PET) seems to be a more effective and noninvasive modality than traditional radiography techniques for scanning the whole body[8]. Although 2-deoxy-2-( 18 F)fluoro-D-glucose ( 18 F-FDG) PET has a low sensitivity, between 36% and 70%, in detecting HCC[9-11], the application of PET-CT for diagnosing HCC has made great progress in recent years. This review presents an overview of the current status and future prospects of PET for diagnosing HCC.…”

Section: Introductionmentioning

confidence: 99%

Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects

Rencai¹,

She²,

Gao³

et al. 2019

WJG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality worldwide. Various imaging modalities provide important information about HCC for its clinical management. Since positron-emission tomography (PET) or PET-computed tomography was introduced to the oncologic setting, it has played crucial roles in detecting, distinguishing, accurately staging, and evaluating local, residual, and recurrent HCC. PET imaging visualizes tissue metabolic information that is closely associated with treatment. Dynamic PET imaging and dual-tracer have emerged as complementary techniques that aid in various aspects of HCC diagnosis. The advent of new radiotracers and the development of immuno-PET and PET-magnetic resonance imaging have improved the ability to detect lesions and have made great progress in treatment surveillance. The current PET diagnostic capabilities for HCC and the supplementary techniques are reviewed herein.

show abstract

Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors

Abstract: A preoperative 18F-FDG PET scan can be considered a useful reference for postoperative tumor recurrence and histopathological differentiation in cases of primary malignant intrahepatic tumors. 18F-FDG PET scan results should be interpreted separately for malignant liver tumors.

Cited by 21 publications

References 45 publications

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Prognostic Significance of¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study

Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects

Contact Info

Product

Resources

About

Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors

Abstract: A preoperative 18F-FDG PET scan can be considered a useful reference for postoperative tumor recurrence and histopathological differentiation in cases of primary malignant intrahepatic tumors. 18F-FDG PET scan results should be interpreted separately for malignant liver tumors.

Cited by 21 publications

References 45 publications

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer

Prognostic Significance of18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study

Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects

Contact Info

Product

Resources

About

Prognostic Significance of¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study